GlassScriptOncology Testing/Genetic Disease Testing
Payments companies reported to CMS as associated with Oncology Testing/Genetic Disease Testing. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oncology Testing/Genetic Disease Testing, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oncology Testing/Genetic Disease Testing
These are the largest totals companies reported as associated with Oncology Testing/Genetic Disease Testing. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Baljit Singh | New York, NY | Anatomic Pathology | $393.00 |
| Robert Babkowski | Stamford, CT | Anatomic Pathology & Clinical Pathology | $375.00 |
| Dorothy Wong | Campbell, CA | Anatomic Pathology & Clinical Pathology | $373.00 |
| Colby Cantu | Jacksonville, FL | Anatomic Pathology & Clinical Pathology | $275.00 |
| Valentin Robu | Greenville, SC | Anatomic Pathology & Clinical Pathology | $113.00 |
Prescribed Oncology Testing/Genetic Disease Testing?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.